Glenmark Pharmaceuticals has reported results for fourth quarter and year ended March 31, 2019.
The company has reported a rise of 26.99% in its net profit at Rs 281.29 crore for the quarter under review as compared to Rs 221.51 crore for the same quarter in the previous year. Total income of the company increased by 17.82% at Rs 1,755.67 crore for Q4FY19 as compared Rs 1,490.12 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported a rise of 6.61% in its net profit at Rs 161.66 crore for the quarter under review as compared to Rs 151.63 crore for the same quarter in the previous year. Total income of the company increased by 10.78% at Rs 2,602.53 crore for Q4FY19 as compared Rs 2,349.37 crore for the corresponding quarter previous year.
For the year ended March 31, 2019, the company has reported a rise of 59.92% in its net profit at Rs 1,622.11 crore as compared to Rs 1,014.35 crore for the previous year. Total income of the company increased by 18.45% at Rs 6,780.48 crore for year under review as compared to Rs 5,724.20 crore for year ended March 31, 2018.
For the year ended March 31, 2019, on the consolidated basis, the company has reported a rise of 15.07% in its net profit at Rs 925.00 crore as compared to Rs 803.87 crore for the previous year. Total income of the company increased by 9.56% at Rs 10,073.61 crore for year under review as compared to Rs 9,194.47 crore for year ended March 31, 2018.